News >

Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care

Lisa Miller
Published: Friday, Jul 28, 2017

Dr Sara M. Tolaney

Sara M. Tolaney, MD, MPH
Trastuzumab (Herceptin) remains a standard of care in the neoadjuvant and adjuvant treatment settings for patients with HER2-positive breast cancer. Sara M. Tolaney, MD, is trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in this patient population without added toxicities.

“One approach I have taken is to use TCH in patients with cardiac risk factors and AC-TH in most other patients,” she said.

Trastuzumab in Combination

“While outcomes for HER2-positive disease have dramatically improved with the addition of trastuzumab, approximately 15% of women with early stage HER2-positive disease still recur, so there is a need to do better,” Tolaney said.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x